Mitomycin - systemic

"Mitomycin – systemic" is a route-specific administrative grouping rather than an independent pharmacologic class, referring to systemic formulations of the antineoplastic antibiotic and alkylating agent mitomycin Functioning primarily as an intravenous chemotherapy, it undergoes intracellular enzymatic bioreduction to generate reactive intermediates that covalently cross-link DNA, inhibiting cellular replication and transcription

"Mitomycin – systemic" is a route-specific administrative grouping rather than an independent pharmacologic class, referring to systemic formulations of the antineoplastic antibiotic and alkylating agent mitomycin Clinically, systemic mitomycin is utilized in combination antineoplastic regimens to treat gastrointestinal malignancies—most notably gastric and pancreatic adenocarcinomas, as well as squamous cell carcinoma of the anal canal—distinguishing these applications from localized intravesic...

Functioning primarily as an intravenous chemotherapy, it undergoes intracellular enzymatic bioreduction to generate reactive intermediates that covalently cross-link DNA, inhibiting cellular replication and transcription Clinically, systemic mitomycin is utilized in combination antineoplastic regimens to treat gastrointestinal malignancies—most notably gastric and pancreatic adenocarcinomas, as well as squamous cell carcinoma of the anal canal—distinguishing these applications from localized int...

Clinically, systemic mitomycin is utilized in combination antineoplastic regimens to treat gastrointestinal malignancies—most notably gastric and pancreatic adenocarcinomas, as well as squamous cell carcinoma of the anal canal—distinguishing these applications from localized intravesical, intracavitary, or ophthalmic formulations